Decisions regarding treatment choice or physician-mediated switching must be a clinical decision made by a treating physician on an individual patient basis, supported by scientific evidence, and with patient awareness.
Watch the video to discover more about the Potential Benefits of Switching to a Biosimilar:
*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
†Remicade® is a registered trademark of MSD.
PP-IFA-GBR-0310. December 2018